Announcements
news
20160901
September 1, 2016 Quantum Model Repurposing of Cetromycin for Liver Stage Malaria Project Narrative: Cethromycin was identified by a published quantum model computational analysis for liver- stage malaria drugs. This cethromycin preclinical mouse malaria liver-stage work will build a more solid evidence base for a phase 2, controlled human malaria infection clinical trial. The long-term outcome will be a new safe, effective malaria prophylaxis drug and/or a replacement of primaquine for the dormant liver-stage of P. vivax/ovale. Link to the FOA Link to NIH RePORT |
20161022
October 22, 2016 Ergot Derivative Compound and Its Use in African Sleeping Sickness and Related Disease Provisional patent application No. 62/411404 was filed on October 21,
2016. |
20160902
September 2, 2016 Discovery of New Chemical Entities for Alzheimer's Disease Tauopathy The project is supported by a Phase I SBIR grant award from the National Institute on Aging (1R43AG053137-01A1). Experimental work will be subcontracted to the laboratory of Dr. Kuret at Ohio State University.
Project Narrative: Alzheimer’s disease is the most prevalent dementing illness of the elderly. It is defined in part by the appearance of cellular lesions composed of aggregates of the microtubule-associated protein tau. This project seeks to identify novel tau aggregation inhibitors as potentially disease modifying therapeutics for AD. Link to NIH RePORT |
20150507
May 07, 2015 Discovery of Novel Liver-Stage Antimalarials through Quantum Similarity The research was performed in a collaboration with Dr. David Sullivan, Johns Hopkins Bloomberg School of Public Health, and was supported by the Bill & Melinda Gates Foundation. One of the newly identified compounds, cethromycin, is a drug with an extensive safety profile warranting its exploitation as a new weapon for the current effort of malaria eradication. |
20140901
September 1, 2014 Macrolide Compounds and Their Use in Liver Stage Malaria and Related Disease Provisional patent application No. 62/411404 was filed on 25 August 2014. |
20140502
May 2, 2014 A Quantum Similarity Approach for the Discovery of Anti-Trypanosome Drug Leads The project is supported by a Phase I SBIR grant award from the National Institute of Allergies and Infectious Diseases (1R43AI114078-01). The experimental work will be subcontracted to the laboratory of Dr. Kojo Mensa-Wilmot at the University of Georgia. Project Narrative: Human African trypanosomiasis (HAT) or 'sleeping sickness' is a neglected tropical disease caused by the parasite Trypanosoma brucei. Here, we propose to apply a quantum-similarity approach to discover novel inhibitors of T. Brucei. Quantum similarity takes modeling of bio-molecular interactions a step further and uses first principles of quantum theory alone to describe the whole system rather than just the central part. This allows for simultaneous interrogation of multiple targets and pathways, and incorporation of various pharmacological requirements early in the drug discovery process, thus increasing the chances of finding novel therapeutics to reduce CNS invasion and ameliorate immune mediated pathology in this parasitic CNS infection. |
20130902
September 2, 2013 Discovery of Novel Antipsychotics through Quantum Similarity The project is supported by a Phase I SBIR grant award from the National Institute of Mental Health (1R43MH101892-01). The experimental work will be subcontracted to the laboratory of Dr. Andrea Giuffrida, at the University of Texas Health Science Center at San Antonio. Project Narrative: Schizophrenia is a complex psychiatric disorder with a heterogeneous clinical phenotype. It is one of the most costly psychiatric illnesses, not only in terms of direct cost but also as a result of its long-term impact and loss of productivity, requirig intensive medical psychiatric care as well as the indefinite need for social and economic support. Here, we propose to apply a quantum-similarity approach to discover novel modulators (inhibitors) of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), aiming to elevate endocannabinoid tone to relieve the negative symptoms of schizophrenia. |
20130101
January 7, 2013 Development of Small Molecules for Use in Diagnostic Devices to Measure Plasma Renin Activity The project is funded by the EU Fund for Regional Development and being executed in Bulgaria. |
1-10 of 14